GPX4 and neuroblastoma: In vitro, myricetin treatment of SH-SY5Y neuroblastoma cells exposed to 1-methyl-4-phenylpyridine (MPP+) significantly reduces Fe2+ and ROS levels, activates the NRF2/GPX4 signaling pathway, suppresses neuronal ferroptosis, and mitigates cellular injury (Gu et al., 2024).